Chief Operating Officer, Executive Vice President of Research & Development at WUGEN Inc - St. Louis, MO, US
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.